-
Mashup Score: 9PI3K Inhibitor Doubles Breast Cancer Survival - 20 day(s) ago
Genentech’s PI3K inhibitor inavolisib (Itovebi) dramatically increased progression-free survival (PFS) in patients with PIK3CA-mutated, hormone receptor–positive, HER2-negative advanced or metastatic breast cancer, according to new research (N Engl J Med 2024 Oct 30 [Epub ahead of print]). In the phase III, double-blind INAVO120 trial, 161 patients received inavolisib plus the CDK inhibitor palbociclib (Ibrance; Pfizer) and the estrogen receptor antagonist fulvestrant and 164 received a placebo with palbociclib and fulvestrant. The median PFS was 15 months in the inavolisib group and 7.3 months in the placebo group. Discontinuation due to adverse events occurred in 6.8% of the patients in the inavolisib group and 0.6% of those in the placebo group.
Source: aacrjournals.orgCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 2Highlighted research articles - 22 day(s) ago
Chimeric antigen receptors (CAR) enable MHC-independence but do not recreate the precise molecular regulation induced by T-cell receptor (TCR) complexes. In an effort to engage endogenous TCR circuits, Chang and colleagues designed MHC-independent TCRs. Using predictive modeling, they found many biochemical and structural conflicts at the synthetic hybrid domain interface. Through iterative modeling and sequence modification, they “evolved” these receptors towards native-like structures, yielding significantly enhanced function across several models of cancer. Combination with 4-1BB costimulation enabled robust tumor control that was more durable than classic second-generation CARs. These observations pave a path for structure-informed design of novel antigen receptors.See article, p. 2109.Targeting oncogenic KRAS, the primary driver of pancreas cancer, holds promise, but responses are limited by acquired resistance. Singhal and colleagues found that acute resistance to KRAS inhibition
Source: aacrjournals.orgCategories: General Medicine News, Oncologists1Tweet-
Read article highlights from the November issue of Cancer Discovery https://t.co/P7EzWgIPkj #InThisIssue https://t.co/nBsRzb6EMT
-
-
Mashup Score: 6
Early Career Award | Cancer Discovery | American Association for Cancer Research .aacrcontent .banner{ width: 100% margin: -20px; } .aacrcontent .banner-sm{ display: none; } .right{float: right; margin: 0 16px 16px 16px; padding: 16px; width: 220px; background-color: #f0f0f0; border: solid 1px #ddd;} .aacrcontent2 { box-shadow: 3px 3px 6px #ccc, -3px -3px 6px #ccc; font-size: 16px; max-width: 400px; padding: 16px;} .copy h3{margin-top: 20px;} /*…
Source: aacrjournals.orgCategories: General Medicine News, Oncologists1Tweet-
Nominations for the Cancer Discovery Early Career Award are now open! Learn more. https://t.co/sWhpH2CvmK https://t.co/EfVvtRqyO2
-
-
Mashup Score: 3
Cancer Discovery | 14 | 11 | November 2024
Source: aacrjournals.orgCategories: General Medicine News, Oncologists1Tweet-
The November issue is online. https://t.co/Ww6j9hs2bj https://t.co/lF9fJImWlb
-
-
Mashup Score: 0
New genetic variants associated with prostate cancer have been discovered in a large-scale genetic study of African men. The finding potentially opens the door to new risk stratification approaches for prostate cancer and highlights the importance of conducting genetic studies in diverse, understudied populations.
Source: aacrjournals.orgCategories: General Medicine News, Onc News and JournalsTweet-
News: New Genetic Associations for Prostate Cancer Found in African Men. Learn more: https://t.co/ZWCWDNP0Iq https://t.co/bMWf9Et01z
-
-
Mashup Score: 1Industry-Sponsored Trials Out-Enrolling NIH’s - 26 day(s) ago
Cancer clinical trials sponsored by industry enrolled more than eight times as many patients as NIH-sponsored trials during 2018–2022. This could mean that cancer research advances may come to gradually align more closely with industry’s priorities.
Source: aacrjournals.orgCategories: General Medicine News, Oncologists1Tweet-
News: Industry-Sponsored Trials Out-Enrolling NIH’s. Learn more: https://t.co/omW3R6yWPh https://t.co/44lAfKbtGu
-
-
Mashup Score: 6$50 Million Gift to Drive Pancreatic Cancer Research - 26 day(s) ago
The University of Michigan announced a $50 million donation from philanthropists Richard and Susan Rogel to establish the Rogel and Blondy Center for Pancreatic Cancer. The center will be housed within the university’s Rogel Cancer Center––created in 2018 with a $150 million gift from the Rogels––and will support translational research and clinical care with the aim of doubling the survival rate of pancreatic cancer in the next 10 years. Currently, the 5-year survival rate sits at 13%.
Source: aacrjournals.orgCategories: General Medicine News, Oncologists1Tweet-
News: $50 Million Gift to Drive Pancreatic Cancer Research. Learn more: https://t.co/8W14JoEPSQ https://t.co/B574ZRBG2B
-
-
Mashup Score: 15Clonal Lineage Tracing with Somatic Delivery of Recordable Barcodes Reveals Migration Histories of Metastatic Prostate Cancer - 26 day(s) ago
Applying a recordable barcode in a prostate cancer model delineates the clonal architecture, seeding topologies, and routes taken by distinct cancer clones that traverse metastatic sites.
Source: aacrjournals.orgCategories: General Medicine News, Onc News and JournalsTweet-
From the October issue: Clonal Lineage Tracing with Somatic Delivery of Recordable Barcodes Reveals Migration Histories of Metastatic #ProstateCancer, by @rserio78 @asiepel @NowakDG et al. https://t.co/Mj4qrn9VKm @Nowak_Lab @CSHL @WeillCornell @WCM_MeyerCancer https://t.co/5AAJ02mYm7
-
-
Mashup Score: 6The History of Chromosomal Instability in Genome-Doubled Tumors - 26 day(s) ago
A novel Bayesian method to time the occurrence of complex copy number gains was applied to thousands of tumor whole genome sequences, allowing the temporal dynamics between whole genome doubling and other copy number events to be evaluated.
Source: aacrjournals.orgCategories: General Medicine News, Oncologists1Tweet-
Read the editors' pick research brief: https://t.co/94EvSx7YbL https://t.co/WexQey6S6s
-
-
Mashup Score: 27RAS Inhibitors Promising for Pancreatic Cancer - 26 day(s) ago
According to research presented at the 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, Spain, held October 23–25, two RAS(ON) inhibitors demonstrated significant efficacy and favorable safety in patients with pancreatic ductal adenocarcinoma (PDAC). The G12D-selective inhibitor RMC-9805 (Revolution Medicines) elicited a 30% objective response rate and 80% disease control rate among 40 patients with PDAC. Among the 99 patients with PDAC who received 1200 mg RMC-9805 daily, only one grade 3 alanine aminotransferase elevation—and no grade 4 or 5 treatment-related adverse events—were reported. The company also announced that the 127 patients with PDAC taking their multi-selective RAS inhibitor, RMC-6236, in a phase I/Ib trial had an overall survival rate of 89% at 6 months, while 8% experienced rash, 3% developed stomatitis, and 2% suffered diarrhea grade 3 or higher.
Source: aacrjournals.orgCategories: General Medicine News, Oncologists1Tweet-
Breaking News: RAS Inhibitors Promising for Pancreatic Cancer https://t.co/byb8BjFvDo https://t.co/vp82yZ19VV
-
News: PI3K Inhibitor Doubles Breast Cancer Survival. https://t.co/oQhTXgVuHv https://t.co/OIFRoFPVtu